David Lee, MD
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Cardiovascular Medicine
Key Documents
Contact Information
-
Clinical Offices
Cardiovascular Medicine Clinic 300 Pasteur Dr MC 5319 A260 Stanford, CA 94305 Tel Work (650) 723-6459 Fax (650) 723-8392
- Academic Offices
Personal Information Email Tel (650) 725-2621Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cardiology (Heart)
- Interventional Cardiology
Professional Education
| Fellowship: | Stanford University School of Medicine CA (1998) |
| Medical Education: | University Of Minnesota MN (1992) |
| M.D.: | University of Minnesota, Medicine (1992) |
| S.B: | M.I.T., Biology (1987) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
1. Use of GP IIb/IIIa inhibitors and other pharmacotherapy in the treatment of acute myocardial infarction
2. Novel treatments and devices for the treatment of acute myocardial infarction
3. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
4. Novel approaches to coronary revascularization
5. Closure devices for atrial septal defects and patent foramen ovale
Clinical Trials
- Recruiting Zenith® Iliac Branch System Clinical Study
- Recruiting Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)
- Not Recruiting FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT
- Not Recruiting TAXUS Libertē Post Approval Study
Publications
- On and off: the dilemma of managing STEMI after hours. J Invasive Cardiol. 2009; (10): 523-4
- Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J Am Coll Cardiol. 2005; (3): 363-8
- Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation. 2003; (11): 1497-501
- Effect of audit on door-to-inflation times in primary angioplasty/stenting for acute myocardial infarction. Am J Cardiol. 2001; (3): 336-8, A9
- Cardiac paraganglioma: diagnostic and surgical challenges. J Card Surg. 2012; (2): 178-82
- Most accurate definition of a high femoral artery puncture: aiming to better predict retroperitoneal hematoma in percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012; (1): 37-42
Help